Arcutis (NASDAQ: ARQT) CFO gets RSU, option grants and sells shares

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. SVP and Chief Financial Officer Latha Vairavan reported both stock awards and small share sales. On February 27, 2026, she received grants of 27,000 Restricted Stock Units (RSUs), each convertible into one common share, vesting 25% annually starting March 1, 2027, and a stock option for 70,000 shares that vests monthly over four years from March 1, 2026.

On March 2, 2026, she sold a total of 2,853 common shares in open‑market transactions at weighted average prices of $25.1605 and $25.9140 per share, in price ranges disclosed in the footnotes, to cover tax‑withholding obligations upon RSU vesting. After these sales, she directly held 87,754 common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vairavan Latha

(Last) (First) (Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE CA 91361

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		A(1)		27,000	A	$0	90,607	D
Common Stock	03/02/2026		S(2)		2,772	D	$25.1605(3)	87,835	D
Common Stock	03/02/2026		S(2)		81	D	$25.914(4)	87,754	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$26.97	02/27/2026		A		70,000		(5)	02/27/2036	Common Stock	70,000	$0	70,000	D

Explanation of Responses:

1. Constitute Restricted Stock Units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the "Vesting Commencement Date"), of each year beginning March 1, 2027, subject to the Reporting Person's continued service to the Issuer.

2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs.

3. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.69 to $25.67, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.70 to $26.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

5. 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

Remarks:

	/s/ Masaru Matsuda, as Attorney-in-Fact for Latha Vairavan	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ARQT CFO Latha Vairavan report on this Form 4?

The filing shows Latha Vairavan received stock awards and sold shares. She was granted 27,000 RSUs and a 70,000-share stock option, and sold 2,853 common shares mainly to cover tax withholding tied to RSU vesting.

How many Arcutis Biotherapeutics (ARQT) shares did the CFO sell and at what prices?

The CFO sold 2,853 ARQT common shares in two open-market transactions. Weighted average prices were $25.1605 and $25.9140 per share, with actual trades occurring within stated ranges between $24.69 and $26.10, as detailed in the footnotes.

Were the ARQT share sales by the CFO discretionary or related to taxes?

The reported ARQT share sales were related to taxes, not discretionary selling. Footnotes explain the 2,853 shares sold were used to cover tax withholding obligations triggered by the vesting of previously granted restricted stock units (RSUs).

What equity awards did the ARQT CFO receive according to this Form 4 filing?

The ARQT CFO received 27,000 Restricted Stock Units and a stock option for 70,000 shares. RSUs vest 25% annually starting March 1, 2027, while one forty-eighth of the option vests monthly from March 1, 2026, over four years.

How many Arcutis Biotherapeutics (ARQT) shares does the CFO own after these transactions?

Following the reported transactions, the CFO directly holds 87,754 ARQT common shares. She also holds a stock option covering 70,000 shares, which will become exercisable gradually according to the specified vesting schedule in the Form 4 footnotes.

How do the RSUs granted to the ARQT CFO vest over time?

The 27,000 RSUs vest in four equal annual installments. Twenty-five percent of the RSUs vest each March 1, beginning March 1, 2027, provided the CFO continues to serve Arcutis Biotherapeutics throughout the vesting period.